{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:11Z","timestamp":1793679191207,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["43885"],"award-info":[{"award-number":["43885"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["42856"],"award-info":[{"award-number":["42856"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["25688"],"award-info":[{"award-number":["25688"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["10124"],"award-info":[{"award-number":["10124"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["17586"],"award-info":[{"award-number":["17586"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["05681"],"award-info":[{"award-number":["05681"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["26276"],"award-info":[{"award-number":["26276"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["03991"],"award-info":[{"award-number":["03991"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["016976"],"award-info":[{"award-number":["016976"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0426-3","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T14:40:28Z","timestamp":1537886428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Non-beta-amyloid\/tau cerebrospinal fluid markers inform staging and progression in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"10","author":[{"given":"Umesh","family":"Gangishetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Christina Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Louneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kollhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Fagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-6777","authenticated-orcid":false,"given":"William T.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"426_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"426_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"426_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1001\/archneur.58.11.1803","volume":"58","author":"GM McKhann","year":"2001","unstructured":"McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick\u2019s Disease. Arch Neurol. 2001;58:1803\u20139.","journal-title":"Arch Neurol"},{"key":"426_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"426_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"426_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/acn3.160","volume":"2","author":"WT Hu","year":"2015","unstructured":"Hu WT, Watts KD, Shaw LM, Howell JC, Trojanowski JQ, Basra S, Glass JD, Lah JJ, Levey AI. CSF beta-amyloid 1-42\u2014what are we measuring in Alzheimer's disease? Ann Clin Transl Neurol. 2015;2:131\u20139.","journal-title":"Ann Clin Transl Neurol"},{"key":"426_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. Jama. 2011;305:275\u201383.","journal-title":"Jama"},{"issue":"4","key":"426_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","volume":"134","author":"Marta Marqui\u00e9","year":"2017","unstructured":"Marquie M, Siao Tick Chong M, Anton-Fernandez A, Verwer EE, Saez-Calveras N, Meltzer AC, Ramanan P, Amaral AC, Gonzalez J, Normandin MD, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak Staging. Acta Neuropathol. 2017;134(4):619-28.","journal-title":"Acta Neuropathologica"},{"key":"426_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","volume":"11","author":"D Bertens","year":"2015","unstructured":"Bertens D, Knol DL, Scheltens P, Visser PJ, Alzheimer\u2019s Disease Neuroimaging Initiative. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease. Alzheimers Dement. 2015;11:511\u201322.","journal-title":"Alzheimers Dement"},{"key":"426_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0172-3","volume":"8","author":"S Shokouhi","year":"2016","unstructured":"Shokouhi S, McKay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP, Alzheimer\u2019s Disease Neuroimaging Initiative. Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther. 2016;8:2.","journal-title":"Alzheimers Res Ther"},{"key":"426_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68:903\u201312.","journal-title":"Biol Psychiatry"},{"key":"426_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","volume":"119","author":"WT Hu","year":"2010","unstructured":"Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010;119:669\u201378.","journal-title":"Acta Neuropathol"},{"key":"426_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1212\/WNL.0b013e318266fa70","volume":"79","author":"WT Hu","year":"2012","unstructured":"Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897\u2013905.","journal-title":"Neurology"},{"key":"426_CR14","doi-asserted-by":"publisher","first-page":"e18850","DOI":"10.1371\/journal.pone.0018850","volume":"6","author":"R Craig-Schapiro","year":"2011","unstructured":"Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One. 2011;6:e18850.","journal-title":"PLoS One"},{"key":"426_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JAD-2006-9309","volume":"9","author":"F Abdi","year":"2006","unstructured":"Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9:293\u2013348.","journal-title":"J Alzheimers Dis"},{"key":"426_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1179\/016164106X98035","volume":"28","author":"EM Castano","year":"2006","unstructured":"Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer\u2019s disease and non-demented elderly subjects. Neurol Res. 2006;28:155\u201363.","journal-title":"Neurol Res"},{"key":"426_CR17","doi-asserted-by":"publisher","first-page":"e0135365","DOI":"10.1371\/journal.pone.0135365","volume":"10","author":"RC Hendrickson","year":"2015","unstructured":"Hendrickson RC, Lee AY, Song Q, Liaw A, Wiener M, Paweletz CP, Seeburger JL, Li J, Meng F, Deyanova EG, et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid. PLoS One. 2015;10:e0135365.","journal-title":"PLoS One"},{"key":"426_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40478-016-0277-8","volume":"4","author":"WT Hu","year":"2016","unstructured":"Hu WT, Watts KD, Tailor P, Nguyen TP, Howell JC, Lee RC, Seyfried NT, Gearing M, Hales CM, Levey AI, et al. CSF complement 3 and factor H are staging biomarkers in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2016;4:14.","journal-title":"Acta Neuropathol Commun"},{"key":"426_CR19","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/01.wnl.0000436625.63650.27","volume":"81","author":"WT Hu","year":"2013","unstructured":"Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanowski JQ, Levey AI. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945\u201352.","journal-title":"Neurology"},{"key":"426_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamaneurol.2013.6030","volume":"71","author":"JR Richardson","year":"2014","unstructured":"Richardson JR, Roy A, Shalat SL, von Stein RT, Hossain MM, Buckley B, Gearing M, Levey AI, German DC. Elevated serum pesticide levels and risk for Alzheimer disease. JAMA Neurol. 2014;71:284\u201390.","journal-title":"JAMA Neurol"},{"key":"426_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2015.06.1890","volume":"12","author":"J Pannee","year":"2016","unstructured":"Pannee J, Gobom J, Shaw LM, Korecka M, Chambers EE, Lame M, Jenkins R, Mylott W, Carrillo MC, Zegers I, et al. Round robin test on quantification of amyloid-beta 1-42 in cerebrospinal fluid by mass spectrometry. Alzheimers Dement. 2016;12:55\u20139.","journal-title":"Alzheimers Dement"},{"key":"426_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"426_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343\u20139.","journal-title":"Arch Neurol"},{"key":"426_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13195-017-0260-z","volume":"9","author":"F Ben Bouallegue","year":"2017","unstructured":"Ben Bouallegue F, Mariano-Goulart D, Payoux P, Alzheimer\u2019s Disease Neuroimaging Initiative. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer\u2019s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther. 2017;9:32.","journal-title":"Alzheimers Res Ther"},{"key":"426_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00231362","volume":"98","author":"JH Veerkamp","year":"1990","unstructured":"Veerkamp JH, Paulussen RJ, Peeters RA, Maatman RG, van Moerkerk HT, van Kuppevelt TH. Detection, tissue distribution and (sub)cellular localization of fatty acid-binding protein types. Mol Cell Biochem. 1990;98:11\u20138.","journal-title":"Mol Cell Biochem"},{"key":"426_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0891-0618(96)00192-5","volume":"12","author":"Y Owada","year":"1996","unstructured":"Owada Y, Yoshimoto T, Kondo H. Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains. J Chem Neuroanat. 1996;12:113\u201322.","journal-title":"J Chem Neuroanat"},{"key":"426_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1468-1331.2010.03273.x","volume":"18","author":"CE Teunissen","year":"2011","unstructured":"Teunissen CE, Veerhuis R, De Vente J, Verhey FR, Vreeling F, van Boxtel MP, Glatz JF, Pelsers MA. Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur J Neurol. 2011;18:865\u201371.","journal-title":"Eur J Neurol"},{"key":"426_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/bj2520191","volume":"252","author":"GD Offner","year":"1988","unstructured":"Offner GD, Brecher P, Sawlivich WB, Costello CE, Troxler RF. Characterization and amino acid sequence of a fatty acid-binding protein from human heart. Biochem J. 1988;252:191\u20138.","journal-title":"Biochem J"},{"key":"426_CR29","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","volume":"30","author":"N Shioda","year":"2010","unstructured":"Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaga K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci. 2010;30:3146\u201355.","journal-title":"J Neurosci"},{"key":"426_CR30","doi-asserted-by":"crossref","unstructured":"Cheon MS, Kim SH, Fountoulakis M, Lubec G. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer\u2019s disease. J Neural Transm Suppl. 2003;67:225-34.","DOI":"10.1007\/978-3-7091-6721-2_20"},{"key":"426_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2016.01.014","volume":"171","author":"K Hamazaki","year":"2016","unstructured":"Hamazaki K, Maekawa M, Toyota T, Iwayama Y, Dean B, Hamazaki T, Yoshikawa T. Fatty acid composition and fatty acid binding protein expression in the postmortem frontal cortex of patients with schizophrenia: a case-control study. Schizophr Res. 2016;171:225\u201332.","journal-title":"Schizophr Res"},{"key":"426_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000105157","volume":"4","author":"B Mollenhauer","year":"2007","unstructured":"Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007;4:366\u201375.","journal-title":"Neurodegener Dis"},{"key":"426_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/JAD-122074","volume":"34","author":"SE O'Bryant","year":"2013","unstructured":"O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R, Texas Alzheimer's R, Care C. Biomarkers of Alzheimer\u2019s disease among Mexican Americans. J Alzheimers Dis. 2013;34:841\u20139.","journal-title":"J Alzheimers Dis"},{"key":"426_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clineuro.2012.06.004","volume":"115","author":"SY Park","year":"2013","unstructured":"Park SY, Kim MH, Kim OJ, Ahn HJ, Song JY, Jeong JY, Oh SH. Plasma heart-type fatty acid binding protein level in acute ischemic stroke: comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome. Clin Neurol Neurosurg. 2013;115:405\u201310.","journal-title":"Clin Neurol Neurosurg"},{"key":"426_CR35","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1038\/tp.2016.252","volume":"7","author":"K Hoglund","year":"2017","unstructured":"Hoglund K, Kern S, Zettergren A, Borjesson-Hansson A, Zetterberg H, Skoog I, Blennow K. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry. 2017;7:e995.","journal-title":"Transl Psychiatry"},{"key":"426_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.biopsych.2013.11.032","volume":"75","author":"O Harari","year":"2014","unstructured":"Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, et al. Phosphorylated tau-Abeta42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry. 2014;75:723\u201331.","journal-title":"Biol Psychiatry"},{"key":"426_CR37","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/JAD-2010-101293","volume":"22","author":"D Chiasserini","year":"2010","unstructured":"Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer\u2019s disease. J Alzheimers Dis. 2010;22:1281\u20138.","journal-title":"J Alzheimers Dis"},{"key":"426_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-8-39","volume":"8","author":"RS Desikan","year":"2013","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, et al. Heart fatty acid binding protein and Abeta-associated Alzheimer\u2019s neurodegeneration. Mol Neurodegener. 2013;8:39.","journal-title":"Mol Neurodegener"},{"key":"426_CR39","doi-asserted-by":"crossref","unstructured":"Merluzzi AP, Carlsson CM, Johnson SC, Schindler SE, Asthana S, Blennow K, Zetterberg H, Bendlin BB. Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology. 2018.","DOI":"10.1212\/WNL.0000000000005901"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0426-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0426-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0426-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:32:23Z","timestamp":1589542343000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0426-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0426-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Institutional Review Boards at Emory University, University of Pennsylvania, and Washington University. All participants previously consented to CSF storage and analysis of stored CSF samples.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LMS has received personal compensation for activities with Roche Diagnostics which produces CSF amyloid and tau assays. AMF is on the Scientific Advisory Boards for Roche Diagnostics which produces CSF amyloid and tau assays. WTH consults for ViveBio, LLC., which manufactures lumbar puncture trays; has a patent (assignee: Emory University) on the use of CSF p\/t-Tau ratio in the evaluation of FTLD; has received research support from Fujirebio USA and Avid Pharmaceuticals; has received travel support from Hoffman La Roche and Abbvie. The remaining authors declare that they have no competing interests,","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"98"}}